Literature DB >> 30062966

Ultrasound-Targeted Delivery Technology: A Novel Strategy for Tumor- Targeted Therapy.

Meng Du1, Zhiyi Chen1, Yuhao Chen1, Yue Li1.   

Abstract

BACKGROUND: Ultrasound has been widely used in clinical diagnosis because it is noninvasive, inexpensive, simple, and reproducible. With the development of molecular imaging, material science, and ultrasound contrast agents, ultrasound-targeted delivery technology has emerged. The interaction of ultrasound and molecular probes can be exploited to change the structures of cells and tissues in order to promote the targeted release of therapeutic substances to local tumors. The targeted delivery of drugs, genes, and gases would not only improve the efficacy of tumor treatment but also avoid the systemic toxicity and side effects caused by antitumor treatments. This technology was recently applied in clinical trials and showed enormous potential for clinical application.
OBJECTIVE: This article briefly introduces the characteristics of the tumor microenvironment and the principle of ultrasound-targeted delivery technology. To present recent progress in this field, this review focuses on the application of ultrasound-targeted delivery technology in tumor-targeted therapy, including drug delivery, gene transfection, and gas treatment.
RESULTS: The results of this study show that ultrasound-targeted delivery technology is a promising therapeutic strategy for tumor treatment.
CONCLUSION: Ultrasound-targeted delivery technology shows promise with regard to cancer treatment. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Drug delivery; gas treatment; gene therapy; microbubble; targeted therapy; tumor; ultrasound.

Mesh:

Year:  2019        PMID: 30062966     DOI: 10.2174/1389450119666180731095441

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  4 in total

1.  The better effects of microbubble ultrasound transfection of miR-940 on cell proliferation inhibition and apoptosis promotion in human cervical cancer cells.

Authors:  Xiaojun Xiao; Yujuan Zhang; Qi Lin; Keli Zhong
Journal:  Onco Targets Ther       Date:  2019-08-21       Impact factor: 4.147

2.  CMBs carrying PTX and CRISPR/Cas9 targeting C‑erbB‑2 plasmids interfere with endometrial cancer cells.

Authors:  Siyuan Peng; Junhong Cai; Shan Bao
Journal:  Mol Med Rep       Date:  2021-09-30       Impact factor: 2.952

3.  Accurately Controlled Delivery of Temozolomide by Biocompatible UiO-66-NH2 Through Ultrasound to Enhance the Antitumor Efficacy and Attenuate the Toxicity for Treatment of Malignant Glioma.

Authors:  Zhiping Wan; Chunlin Li; Jinmao Gu; Jun Qian; Junle Zhu; Jiaqi Wang; Yinwen Li; Jiahao Jiang; Huairui Chen; Chun Luo
Journal:  Int J Nanomedicine       Date:  2021-10-09

Review 4.  α-Synuclein Radiotracer Development and In Vivo Imaging: Recent Advancements and New Perspectives.

Authors:  Obada M Alzghool; Guus van Dongen; Elsmarieke van de Giessen; Linda Schoonmade; Wissam Beaino
Journal:  Mov Disord       Date:  2022-03-15       Impact factor: 9.698

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.